Ozempic Alternatives & Comparison

Neither drug carries a weight-loss label — both treat type 2 diabetes, and both get prescribed off-label for weight constantly. SURPASS-2 compared them directly: −11.2 kg on Mounjaro 15 mg against −5.7 kg on Ozempic 1 mg over 40 weeks, with a larger A1C drop too. Ozempic carries the completed cardiovascular result — MACE −26% in SUSTAIN-6. Retail pricing is close, near $1,000 either way, and neither has a real manufacturer cash-pay tier for weight loss.

Both weekly GLP-1s for type 2 diabetes, and Ozempic is the stronger on both endpoints people ask about: −6.5 kg against Trulicity's −3.0 kg, and MACE −26% in SUSTAIN-6 against −12% in REWIND. One caveat worth stating, because it cuts the other way: REWIND enrolled a majority who had not yet had a cardiovascular event, which is a harder population in which to show benefit. Retail is close, near $990 either way, with savings cards limited to commercial insurance.

Identical drug, two delivery routes, and the route is the whole difference. Ozempic is injected weekly; Rybelsus is a daily tablet requiring a strict fast before and after, because the SNAC absorption enhancer only works on an empty stomach. On outcomes, SUSTAIN-6 showed superiority for MACE (HR 0.74) while PIONEER 6 showed non-inferiority (HR 0.79). Retail is around $1,029 and $998. Choose on whether a daily fasting routine or a weekly needle fits your life better.

Semaglutide both times, from the same manufacturer, at different target doses and against different labels. Wegovy climbs to 2.4 mg for weight management; Ozempic tops out at 2 mg for diabetes. Each has its own cardiovascular result in its own population — SELECT's MACE −20% in obesity without diabetes, SUSTAIN-6's −26% in diabetes at high risk. Wegovy has a $349–$499 cash tier; Ozempic has none. Which one you can get is usually decided by which diagnosis is on the prescription.